

31 May 2013

The Manager Companies  
ASX Limited  
20 Bridge Street  
Sydney NSW 2000

(1 page by email)

Dear Madam

### **R&D Tax Incentive**

Biotron Limited (ASX: BIT) is pleased to announce that it has received an R&D Tax Incentive refund of \$891,951 for the 2011/12 financial year.

The R&D Tax Incentive is an Australian Government program under which companies receive cash refunds for 45% of eligible expenditure on research and development.

The incentive refund results from expenditure on Biotron's HIV and Hepatitis C virus (HCV) drug development programs. Dr Miller commented: "This cash rebate strengthens Biotron's cash position and is an important source of funds for the Company's research and development activities."

#### Enquiries


Dr Michelle Miller  
Managing Director  
Biotron Limited  
+61-2 9805 0488  
+61-(0)412313329

Rudi Michelson  
Monsoon Communications  
+61-3 9620 3333

#### **About Biotron**

Biotron Limited is engaged in the research, development, and commercialisation of drugs targeting significant viral diseases with unmet medical need, with a major focus on HIV and HCV. The Company has BIT225 in clinical development for both HIV and HCV, and also has several earlier stage preclinical and research programs for several other viral infections including Dengue.

Yours sincerely



Peter J. Nightingale  
Company Secretary

pjn7252